Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04054167
Recruitment Status : Recruiting
First Posted : August 13, 2019
Last Update Posted : August 13, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:
This phase II trial studies how well ultra low dose radiation works before or after chemotherapy-free targeted therapy in treating patients with mantle cell lymphoma that has come back or does not respond to treatment. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. Ultra low dose radiation is generally associated with a lower risk of side effects which may allow patients to be able to receive low-dose radiation therapy more often than high-dose radiation therapy. This trial may help doctors learn if giving ultra low dose radiation helps control mantle cell lymphoma and improves response to chemotherapy free targeted therapy.

Condition or disease Intervention/treatment Phase
Recurrent Mantle Cell Lymphoma Refractory Mantle Cell Lymphoma Drug: Low Dose Radiation Therapy Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. To evaluate the efficacy of adding ultra low dose radiation (ULDR) to chemotherapy free-targeted therapy (CTFTT) in contributing to a durable overall response in treated locations by estimating overall response rate (ORR) at 3 months.

SECONDARY OBJECTIVES:

I. To evaluate if ULDR can improve progression-free survival and overall survival.

II. To evaluate the prognostic factors associated with inferior progression-free survival, including patient related and previous treatment related and if radiation can overcome these prognostic factors.

III. To evaluate if radiation helps to bridge patients to other investigational drugs, by decreasing the disease bulk, controlling their symptoms, and maintaining a good performance status.

OUTLINE:

Patients undergo ultra low dose radiation for 1-2 days before chemotherapy free-targeted therapy. Patients may receive a second, longer course of radiation if the lesion treated does not respond.

After completion of study treatment, patients are followed up every 6 months for up to 5 years.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial to Assess the Efficacy of Ultra Low Radiation Dose Delivered Prior or After Chemotherapy Free Targeted Therapy for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Actual Study Start Date : June 14, 2019
Estimated Primary Completion Date : May 29, 2021
Estimated Study Completion Date : May 29, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: Treatment (ultra low dose radiation therapy)
Patients undergo ultra low dose radiation for 1-2 days before chemotherapy free-targeted therapy. Patients may receive a second, longer course of radiation if the lesion treated does not respond.
Drug: Low Dose Radiation Therapy
Undergo ultra low dose radiation
Other Name: Low Dose Radiation




Primary Outcome Measures :
  1. Overall response rate (ORR) [ Time Frame: At 3 months ]
    ORR will be based on the tumors residing within the radiated field using the sum of the longest tumoral axes treated. Responses are defined as follows: i) complete response (CR): > 75% reduction in the sum of the longest tumoral axes treated within a radiation field; ii) partial response (PR): 50 to 75% reduction; and stable disease (SD): a reduction < 50%. Progressive disease will be defined as any relative increase in the sum of the longest tumoral axes within the radiated field. ORR will be assessed by positron emission tomography (PET)/computed tomography (CT) at 3-months after the conclusion of ultra low dose radiation (ULDR). The Lugano Classification will be used to assess tumor response. Will estimate ORR at 3 months by providing an exact 95% confidence interval for the evaluable study population.


Secondary Outcome Measures :
  1. Progression-free survival (PFS) [ Time Frame: From the start of ULDR treatment to the time of a progression or death, assessed up to 5 years ]
    Will be estimated at select time points of interest using the Kaplan-Meier method for all patients enrolled in the study. The origination point for time will begin at the inception of ULDR. Cox proportional hazards regression will be used to evaluate potential prognostic factors.

  2. Overall survival [ Time Frame: From the start of ULDR treatment to the time of death or loss to follow-up, assessed up to 5 years ]
    Will be estimated at select time points of interest using the Kaplan-Meier method for all patients enrolled in the study. The origination point for time will begin at the inception of ULDR. Cox proportional hazards regression will be used to evaluate potential prognostic factors.

  3. ATM mutational status [ Time Frame: At 3 months ]
    Logistic regression will be utilized to assess the effect of patient characteristics such as ATM mutational status, on the Overall Response Rate(ORR ).

  4. PET/CT metabolic parameters [ Time Frame: At 3 months ]
    Logistic regression will be utilized to assess the effect of patient characteristics such PET/CT metabolic parameters, on the Overall Response Rate (ORR).

  5. The Descriptive Statistics of Patient Characteristics of the Transitions to other Investigational Drugs. [ Time Frame: Up to 5 years ]
    Will be used to summarize patient characteristics such as transitions to other investigational drugs at select time points in a patient's follow-up domain. These summaries will indicate if ULDR helps to bridge patients to other investigational drugs, by decreasing the disease bulk, controlling their symptoms, and maintaining a good performance status.

  6. The Descriptive Statistics of Patient Characteristics of the Patients Disease Bulk. [ Time Frame: Up to 5 years ]
    Will be used to summarize patient characteristics such as disease bulk at select time points in a patient's follow-up domain. These summaries will indicate if ULDR helps to bridge patients to other investigational drugs, by decreasing the disease bulk, controlling their symptoms, and maintaining a good performance status.

  7. The Descriptive Statistics of Patient Characteristics of the Patients Symptoms. [ Time Frame: Up to 5 years ]
    Will be used to summarize patient characteristics such as symptoms at select time points in a patient's follow-up domain. These summaries will indicate if ULDR helps to bridge patients to other investigational drugs, by decreasing the disease bulk, controlling their symptoms, and maintaining a good performance status.

  8. The Descriptive Statistics of Patient Characteristics of the Patients Performance status [ Time Frame: Up to 5 years ]
    Will be used to summarize patient characteristics such as performance status at select time points in a patient's follow-up domain. These summaries will indicate if ULDR helps to bridge patients to other investigational drugs, by decreasing the disease bulk, controlling their symptoms, and maintaining a good performance status.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have a confirmed diagnosis of mantle cell lymphoma with positivity in tissue biopsy. Biopsy does not need to be done of the lesions to be treated.
  • Patients must have previously treated relapsed and/or refractory mantle cell lymphoma (MCL) with at least 2 prior lines of therapy (prior carfilzomib, ibrutinib, bortezomib, anthracycline, rituximab or stem cell transplant are acceptable). There is no upper limit for prior lines of therapy.
  • Patients must have demonstrated progressive disease on positron emission tomography (PET)/computed tomography (CT) imaging following ibrutinib treatment, mono- or combinatorial therapy, in the relapsed/refractory setting.
  • Understand and voluntarily sign an Institutional Review Board (IRB)-approved informed consent form.
  • Patients must have bi-dimensional measurable disease (measurable disease by CT scan defined as at least 1 lesion that measures >= 1.5 cm in single dimension.) Patient presenting with lesions in the as at least 1 lesion that measures >= 1.5 cm in single dimension.) Patient presenting with lesions in the presence of leukemia phase (peripheral blood involvement), non-measurable disease, gastrointestinal (GI) MCL, or bone marrow (BM) MCL are also eligible.
  • Gastrointestinal or bone marrow or spleen only patients are allowable and will be analyzed separately.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less.
  • Willing and able to participate in all study related procedures and therapy including swallowing capsules without difficulty.
  • Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test and must be willing to use acceptable methods of birth control during the study and for 30 days after the last dose of study treatment.
  • Male patients must use an effective barrier method of contraception during the study and for 30 days following the last dose of study treatment if sexually active with a female of childbearing potential.
  • Serum bilirubin less than 1.5 mg/dl.
  • Creatinine (Cr) clearance greater than or equal to 30 mL/min.
  • Platelet count greater than 25,000/mm^3.
  • Absolute neutrophil count (ANC) greater than 1,000/mm^3.
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) less than 3 x upper limit of normal or less than 5 x upper limit of normal if hepatic metastases are present.
  • Patients who have bone marrow infiltration by MCL are eligible if their ANC is greater than or equal to 1000/mm^3 (growth factor not allowed) or their platelet level is greater than or equal to 25,000/mm^3.

Exclusion Criteria:

  • Has had prior radiation therapy to the potential radiation target such that additional radiation therapy is considered unsafe by the treating radiation oncologist.
  • Has a diagnosis of active scleroderma or lupus or any other autoimmune disease that by the opinion of the treating radiation oncologist would put the patient at unacceptable risk of toxicity.
  • Any serious medical condition including but not limited to, uncontrolled hypertension, uncontrolled diabetes mellitus, uncontrolled infection, active/symptomatic coronary artery disease, chronic obstructive pulmonary disease (COPD), renal failure, active hemorrhage, or psychiatric illness that, in the investigators opinion places the patient at unacceptable risk and would prevent the subject from signing the informed consent form.
  • Pregnant or breast-feeding females.
  • All patients with central nervous system lymphoma that needs attention prior to treatment of the lesions.
  • If the total fields of radiation will include a marrow volume of more than 40%. Physician can include as many fields to respect the 40% of marrow volume and come back in 4-6 weeks later to address the rest of the disease after insuring that the blood counts are adequate. Blood counts should be back to back to the numbers prior to starting the first phase of radiation + or - 10% variance.
  • If giving radiation prevents them from going through an alternative phase I trial that could be beneficial like chimeric antigen receptor (car) T cell treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04054167


Contacts
Layout table for location contacts
Contact: Bouthaina S Dabaja 713-792-5132 bdabaja@mdanderson.org

Locations
Layout table for location information
United States, Texas
M D Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Bouthaina S. Dabaja    713-792-5132      
Principal Investigator: Bouthaina S. Dabaja         
Sponsors and Collaborators
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Bouthaina S Dabaja M.D. Anderson Cancer Center

Additional Information:
Layout table for additonal information
Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT04054167     History of Changes
Other Study ID Numbers: 2018-0348
NCI-2019-01729 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
2018-0348 ( Other Identifier: M D Anderson Cancer Center )
P30CA016672 ( U.S. NIH Grant/Contract )
First Posted: August 13, 2019    Key Record Dates
Last Update Posted: August 13, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, Mantle-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin